In this episode, we speak with Anita Brickman, CEO of the Plasma Protein Therapeutics Association (PPTA), about the crucial and often misunderstood role of plasma-derived therapies in respiratory health. The discussion highlights how essential plasma donors are for the creation of life-saving medicines used to treat Alpha-1 Antitrypsin Deficiency (AATD) and other rare, chronic conditions. Together, we explore the rigorous global safety standards, the difference between plasma-derived therapies and traditional drugs, and the ongoing challenge of meeting the growing worldwide need for plasma donations.👇 Learn more and explore additional resources:🔹 Episode recap and resources https://chroniclungdiseases.com/en/news/understanding-patient-support-programs-in-alpha-1/🔹 Living Well with COPD – AATD Module (free) https://chroniclungdiseases.com/register🔹 Plasma Week www.plasmaweek.org 🔹 Alpha-1 www.alpha1.org🔹 PPTA Global www.PPTAGlobal.org🔹 AlphaNet Canada https://alphanetcanada.ca/🔹 Canadian Thoracic Society AATD Guidelines https://www.tandfonline.com/doi/full/10.1080/24745332.2024.2443178🔹 Learn more about Season 5 https://chroniclungdiseases.com/en/the-expand-podcast-season-5-aatd/🔹 Watch more episodes about Alpha-1 https://www.youtube.com/playlist?list=PLKERLVA6ikI5X8SabIgyphzutdp8RyKUBThis podcast is produced by RESPIPLUS™ with support from Takeda Canada to raise awareness about Alpha-1 and improve access to care across Canada.